All In MedTech

FDA Clearance Tracker · P160049

STELLAREX 0.035 OTW DRUG-COATED ANGIOPLASTY BALLOON

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jul 26, 2017 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jul 26, 2017

Approved

Time to decision

266 days

Received Nov 2, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P160049
Device name
STELLAREX 0.035 OTW DRUG-COATED ANGIOPLASTY BALLOON
Applicant location
Fremont, CA
Received
Nov 2, 2016
Decided
Jul 26, 2017
Decision
Approved
Supplements
24 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code ONU

FDA's approval statement

As written in FDA's record.

Approval of the Stellarex 0.035 OTW Drug-coated Angioplasty Balloon. This device is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code ONU. The earliest in FDA's data is P130024, decided Oct 9, 2014.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for The Spectranetics Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.